Treatment with a Toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice

Autoimmunity

Volumn 43, Issue 2, 2010, Pages 140-155

  Graham, Kareem L ^a   Lee, Lowen Y ^a   Higgins, John P ^a   Steinman, Lawrence ^b   Utz, Paul J ^a   Ho, Peggy P ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Inhibitory oligos; Systemic lupus erythematosus; Th2; Therapy; Toll like receptors

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; GPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 12; INTERLEUKIN 6; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; C57BL 6 MOUSE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN DEPOSITION; GLOMERULUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY NECROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MESANGIUM CELL; MOUSE; NEPHRITIS; NEW ZEALAND BLACK MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN INTERACTION; PROTEINURIA; SPLEEN CELL; T LYMPHOCYTE; TH2 CELL;

ANIMALS; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 77649289335     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903229239     Document Type: Article

References (51)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996;85: 303-306.
2. Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol 2003;24:595-602.
3. James J, Harley J, Scofield R. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006;18: 462-467. (Pubitemid 44200328)
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-680. (Pubitemid 32747155)
5. Lenert P. Targeting toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 2006;8:203.
6. Cook D, Pisetsky D, Schwartz D. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004;5: 975-979.
7. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway C. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2:253-258.
8. SchnareM,Barton G, Holt A,Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001;2:947-950. (Pubitemid 32976167)
9. Deane J, Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J Immunol 2006;177:6573-6578.
10. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-745.
11. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-607.
12. Viglianti GA, Lau CM, Hanley TM,Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003;19:837-847.
13. Christensen C, Kashgarian M, Alexopoulou L, Flavell R, Akira S, Shlomchik M. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202:321-331.
14. Ho P, Fontoura P, Ruiz P, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol 2003;171:4920-4926.
15. Ho PP, Fontoura P, Platten M, Sobel RA, DeVoss JJ, Lee LY, Kidd BA, Tomooka BH, Capers J, Agrawal A, Gupta R, Zernik J, Yee MK, Lee BJ, Garren H, Robinson WH, Steinman L. A Suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J Immunol 2005;175: 6226-6234.
16. Jacob C, Van Der Meide P, McDevitt H. In vivo treatment of (NZB £ NZW)F1 lupus-like nephritis with monoclonal antibody to gamma-interferon. J Exp Med 1987;166: 798-803.
17. Nakajima A, Hirose S, Yagita H, Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 1997;158:1466-1472.
18. Peng S, Moslehi J, Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997;99: 1936-1946.
19. Balomenos D, Rumold R, Theofilopoulos A. Interferongamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998;101:364-371.
20. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997;186:1623-1631.
21. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JW. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-695.
22. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, Murphy ED, Roths JB, Dixon FJ. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-1215.
23. Wofsy D, SeamanW. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med 1985;161:378-391.
24. Connolly K, Roubinian J, Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4 + T cells is required to suppress autoimmunity. J Immunol 1992;149:3083-3088.
25. Richards H, Satoh M, Jennette J, Croker B, Yoshida H, Reeves W. Interferon-g is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 2001;60: 2173-2180.
26. Santiago M-L, Fossati L, Jacquet C, Muller W, Izui S, Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 1997;185: 65-70.
27. Graham K, Vaysberg M, Kuo A, Utz P. Autoantigen arrays for multiplex analysis of antibody isotypes. Proteomics 2006;6: 5720-5724.
28. Stein C, Subasinghe C, Sinozuka K, Coehn J. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucl Acids Res 1988;16:3209-3221.
29. Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 1986; 13:97-102.
30. Christensen C, Shupe J, Nickerson K, Kashgarian M, Flavell R, Shlomchik M. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417-428.
31. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996;93: 2879-2883.
32. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-1139.
33. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira S, Kelly KM, Reeves WH, Bauer S, Krieg AM. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005;202:1575-1585.
34. Savarese E, Chae O-W, Trowitzsch S, Weber G, Kastner B, Akira S, Wagner H, Schmid RM, Bauer S, Krug A. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006;107:3229-3234.
35. Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, Rifkin IR. Murine dendritic cell type I IFN production induced by human igg-rna immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol 2007;178: 6876-6885.
36. Patole PS, Grone H-J, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlondorff D, Anders H-J. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005;16: 1326-1338.
37. Kirou K, Lee C, George S, Louca K, Peterson M, Crow M. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-1503.
38. Berland R, Fernandez L, Kari E, Han J, Lomakin I, Akira S, Wortis H, Kearney J, Ucci A, Imanishi-Kari T. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 2006;25:429-440.
39. Lau C, Broughton C, Tabor A, Akira S, Flavell R, Mamula M, Christensen S, Shlomchik M, Biglianti G, Rifkin I, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202:1171-1177.
40. Diebold S, Kaisho T, Hemmi H, Akira S, Sousa CE. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531. (Pubitemid 38314425)
41. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004;303:1526-1529.
42. Lund J, Alexopoulou L, Sato A, KarowM, Adams N, Gale N, Iwasaki A, Flavell R. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101:5598-5603.
43. Hemmi H, KaishoT,TakeuchiO, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88- dependent signaling pathway. Nat Immunol 2002;3:196-200.
44. Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: Gene structure, expression, and evolution. Eur Cytokine Netw 2000;11:362-371.
45. Chuang T, Ulevitch R. Cloning and characterization of a sub-family of human toll-like receptors hTLR-7, hTLR-8, and hTLR-9. Eur Cytokine Netw 2000;11:372-378.
46. Pisitkun P, Deane J, Difilippantonio M, Tarasenko T, Saterthwaite A, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006;312:1669-1672.
47. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, Zhou J, Liang C, Bartov G, McDaniel LD, Zhou ZJ, Schultz RA, Wakeland EK. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006; 103:9970-9975.
48. Dong L, Ito S, Ishii K, Klinman D. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB £ NZW mice. Arthritis Rheumat 2005;52:651-658.
49. Patole PS, Zecher D, Pawar RD, Grone H-J, Schlondorff D, Anders H-J. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005;16:3273-3280.
50. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders H-J. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007;18:1721-1731.
51. Krieg A, Vollmer J. Toll-like receptors 7, 8, and 9: Linking innate immunity to autoimmunity. Immunol Rev 2007;220: 251-269.